Literature DB >> 27402080

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

Elvira D'Ippolito1, Ilaria Plantamura1, Lucia Bongiovanni2, Patrizia Casalini3, Sara Baroni1, Claudia Piovan1, Rosaria Orlandi3, Ambra V Gualeni4, Annunziata Gloghini4, Anna Rossini5, Sara Cresta5, Anna Tessari5, Filippo De Braud6, Gianpiero Di Leva7, Claudio Tripodo2, Marilena V Iorio8.   

Abstract

Organization of cancer cells into endothelial-like cell-lined structures to support neovascularization and to fuel solid tumors is a hallmark of progression and poor outcome. In triple-negative breast cancer (TNBC), PDGFRβ has been identified as a key player of this process and is considered a promising target for breast cancer therapy. Thus, we aimed at investigating the role of miRNAs as a therapeutic approach to inhibit PDGFRβ-mediated vasculogenic properties of TNBC, focusing on miR-9 and miR-200. In MDA-MB-231 and MDA-MB-157 TNBC cell lines, miR-9 and miR-200 promoted and inhibited, respectively, the formation of vascular-like structures in vitro Induction of endogenous miR-9 expression, upon ligand-dependent stimulation of PDGFRβ signaling, promoted significant vascular sprouting of TNBC cells, in part, by direct repression of STARD13. Conversely, ectopic expression of miR-200 inhibited this sprouting by indirectly reducing the protein levels of PDGFRβ through the direct suppression of ZEB1. Notably, in vivo miR-9 inhibition or miR-200c restoration, through either the generation of MDA-MB-231-stable clones or peritumoral delivery in MDA-MB-231 xenografted mice, strongly decreased the number of vascular lacunae. Finally, IHC and immunofluorescence analyses in TNBC specimens indicated that PDGFRβ expression marked tumor cells engaged in vascular lacunae. In conclusion, our results demonstrate that miR-9 and miR-200 play opposite roles in the regulation of the vasculogenic ability of TNBC, acting as facilitator and suppressor of PDGFRβ, respectively. Moreover, our data support the possibility to therapeutically exploit miR-9 and miR-200 to inhibit the process of vascular lacunae formation in TNBC. Cancer Res; 76(18); 5562-72. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27402080     DOI: 10.1158/0008-5472.CAN-16-0140

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs.

Authors:  Ruixi Hu; Xiaodong Zhu; Chao Chen; Ruijun Xu; Yifan Li; Wei Xu
Journal:  Cell Prolif       Date:  2018-08-07       Impact factor: 6.831

Review 2.  Emerging roles of microRNAs in cancer.

Authors:  Ivan Vannini; Francesca Fanini; Muller Fabbri
Journal:  Curr Opin Genet Dev       Date:  2018-02-08       Impact factor: 5.578

3.  Downregulation of miR-196-5p Induced by Hypoxia Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma.

Authors:  Hao Zheng; Feng-Rui Bi; Yuan Yang; Yong-Gang Hong; Jun-Sheng Ni; Long Ma; Ming-Hua Liu; Li-Qiang Hao; Wei-Ping Zhou; Li-Hua Song; Hong-Li Yan
Journal:  Horm Cancer       Date:  2019-11-12       Impact factor: 3.869

4.  Plasma microRNA-9 as a diagnostic and prognostic biomarker in patients with esophageal squamous cell carcinoma.

Authors:  Yuantao Cui; Yuan Xue; Shangwen Dong; Peng Zhang
Journal:  J Int Med Res       Date:  2017-06-06       Impact factor: 1.671

5.  ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.

Authors:  E M Langer; N D Kendsersky; C J Daniel; G M Kuziel; C Pelz; K M Murphy; M R Capecchi; R C Sears
Journal:  Oncogene       Date:  2017-10-30       Impact factor: 9.867

Review 6.  MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.

Authors:  Bethany Smith; Priyanka Agarwal; Neil A Bhowmick
Journal:  Endocr Relat Cancer       Date:  2017-03-13       Impact factor: 5.678

7.  Chemotherapy-Induced Extracellular Vesicle miRNAs Promote Breast Cancer Stemness by Targeting ONECUT2.

Authors:  Meng Shen; Chuan Dong; Xianhui Ruan; Wei Yan; Minghui Cao; Donald Pizzo; Xiwei Wu; Lin Yang; Liang Liu; Xiubao Ren; Shizhen Emily Wang
Journal:  Cancer Res       Date:  2019-05-22       Impact factor: 12.701

8.  Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.

Authors:  Jeremy T-H Chang; Fan Wang; William Chapin; R Stephanie Huang
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

9.  MiR-9 Promotes Apoptosis Via Suppressing SMC1A Expression in GBM Cell Lines.

Authors:  Yong Zu; Zhichuan Zhu; Min Lin; Dafeng Xu; Yongjun Liang; Yueqian Wang; Zhengdong Qiao; Ting Cao; Dan Yang; Lili Gao; Pengpeng Jin; Peng Zhang; Jianjun Fu; Jing Zheng
Journal:  Curr Chem Genom Transl Med       Date:  2017-07-31

Review 10.  Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

Authors:  Ramesh Butti; Sumit Das; Vinoth Prasanna Gunasekaran; Amit Singh Yadav; Dhiraj Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.